vs
Consensus Cloud Solutions, Inc.（CCSI）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Consensus Cloud Solutions, Inc.的1.9倍（$168.4M vs $87.1M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 0.1%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -0.6%）
Consensus Cloud Solutions是一家云解决方案提供商，核心产品包括加密数字传真、安全文档交换、工作流程自动化工具，主要面向医疗、法律、金融服务等领域的北美企业客户提供相关服务。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
CCSI vs ESPR — 直观对比
营收规模更大
ESPR
是对方的1.9倍
$87.1M
营收增速更快
ESPR
高出143.6%
0.1%
两年增速更快
ESPR
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $87.1M | $168.4M |
| 净利润 | $20.5M | — |
| 毛利率 | 80.0% | — |
| 营业利润率 | 41.1% | 50.6% |
| 净利率 | 23.5% | — |
| 营收同比 | 0.1% | 143.7% |
| 净利润同比 | 13.5% | — |
| 每股收益（稀释后） | $1.06 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCSIESPR
| Q4 25 | $87.1M | $168.4M | ||
| Q3 25 | $87.8M | $87.3M | ||
| Q2 25 | $87.7M | $82.4M | ||
| Q1 25 | $87.1M | $65.0M | ||
| Q4 24 | $87.0M | $69.1M | ||
| Q3 24 | $87.8M | $51.6M | ||
| Q2 24 | $87.5M | $73.8M | ||
| Q1 24 | $88.1M | $137.7M |
净利润CCSIESPR
| Q4 25 | $20.5M | — | ||
| Q3 25 | $22.1M | $-31.3M | ||
| Q2 25 | $20.8M | $-12.7M | ||
| Q1 25 | $21.2M | $-40.5M | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $21.1M | $-29.5M | ||
| Q2 24 | $23.9M | $-61.9M | ||
| Q1 24 | $26.4M | $61.0M |
毛利率CCSIESPR
| Q4 25 | 80.0% | — | ||
| Q3 25 | 80.0% | — | ||
| Q2 25 | 79.9% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 79.5% | — | ||
| Q3 24 | 79.9% | — | ||
| Q2 24 | 80.4% | — | ||
| Q1 24 | 80.7% | — |
营业利润率CCSIESPR
| Q4 25 | 41.1% | 50.6% | ||
| Q3 25 | 43.2% | -11.4% | ||
| Q2 25 | 44.5% | 8.6% | ||
| Q1 25 | 43.0% | -34.0% | ||
| Q4 24 | 38.4% | -6.4% | ||
| Q3 24 | 43.8% | -31.0% | ||
| Q2 24 | 45.6% | 3.5% | ||
| Q1 24 | 42.7% | 52.5% |
净利率CCSIESPR
| Q4 25 | 23.5% | — | ||
| Q3 25 | 25.2% | -35.9% | ||
| Q2 25 | 23.7% | -15.4% | ||
| Q1 25 | 24.3% | -62.2% | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 24.1% | -57.2% | ||
| Q2 24 | 27.3% | -83.9% | ||
| Q1 24 | 29.9% | 44.3% |
每股收益（稀释后）CCSIESPR
| Q4 25 | $1.06 | $0.32 | ||
| Q3 25 | $1.15 | $-0.16 | ||
| Q2 25 | $1.07 | $-0.06 | ||
| Q1 25 | $1.07 | $-0.21 | ||
| Q4 24 | $0.92 | $-0.14 | ||
| Q3 24 | $1.09 | $-0.15 | ||
| Q2 24 | $1.24 | $-0.33 | ||
| Q1 24 | $1.37 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.7M | $167.9M |
| 总债务越低越好 | $558.4M | — |
| 股东权益账面价值 | $13.8M | $-302.0M |
| 总资产 | $663.8M | $465.9M |
| 负债/权益比越低杠杆越低 | 40.54× | — |
8季度趋势，按日历期对齐
现金及短期投资CCSIESPR
| Q4 25 | $74.7M | $167.9M | ||
| Q3 25 | $97.6M | $92.4M | ||
| Q2 25 | $57.9M | $86.1M | ||
| Q1 25 | $53.4M | $114.6M | ||
| Q4 24 | $33.5M | $144.8M | ||
| Q3 24 | $54.6M | $144.7M | ||
| Q2 24 | $49.2M | $189.3M | ||
| Q1 24 | $61.5M | $226.6M |
总债务CCSIESPR
| Q4 25 | $558.4M | — | ||
| Q3 25 | $578.6M | — | ||
| Q2 25 | $578.2M | — | ||
| Q1 25 | $583.7M | — | ||
| Q4 24 | $593.0M | — | ||
| Q3 24 | $612.5M | — | ||
| Q2 24 | $642.8M | — | ||
| Q1 24 | $671.7M | — |
股东权益CCSIESPR
| Q4 25 | $13.8M | $-302.0M | ||
| Q3 25 | $-2.6M | $-451.4M | ||
| Q2 25 | $-26.5M | $-433.5M | ||
| Q1 25 | $-49.4M | $-426.2M | ||
| Q4 24 | $-79.5M | $-388.7M | ||
| Q3 24 | $-93.2M | $-370.2M | ||
| Q2 24 | $-124.4M | $-344.2M | ||
| Q1 24 | $-151.8M | $-294.3M |
总资产CCSIESPR
| Q4 25 | $663.8M | $465.9M | ||
| Q3 25 | $675.0M | $364.0M | ||
| Q2 25 | $641.5M | $347.1M | ||
| Q1 25 | $629.6M | $324.0M | ||
| Q4 24 | $602.2M | $343.8M | ||
| Q3 24 | $622.5M | $314.1M | ||
| Q2 24 | $608.5M | $352.3M | ||
| Q1 24 | $620.8M | $373.1M |
负债/权益比CCSIESPR
| Q4 25 | 40.54× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.2M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $7.3M | — |
| 自由现金流率自由现金流/营收 | 8.4% | — |
| 资本支出强度资本支出/营收 | 9.1% | 0.0% |
| 现金转化率经营现金流/净利润 | 0.74× | — |
| 过去12个月自由现金流最近4个季度 | $105.9M | — |
8季度趋势，按日历期对齐
经营现金流CCSIESPR
| Q4 25 | $15.2M | $45.2M | ||
| Q3 25 | $51.6M | $-4.3M | ||
| Q2 25 | $28.3M | $-31.4M | ||
| Q1 25 | $40.9M | $-22.6M | ||
| Q4 24 | $11.1M | $-35.0M | ||
| Q3 24 | $41.6M | $-35.3M | ||
| Q2 24 | $24.4M | $-7.2M | ||
| Q1 24 | $44.7M | $53.8M |
自由现金流CCSIESPR
| Q4 25 | $7.3M | — | ||
| Q3 25 | $44.4M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $33.7M | — | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $33.6M | $-35.5M | ||
| Q2 24 | $15.8M | $-7.3M | ||
| Q1 24 | $35.8M | $53.8M |
自由现金流率CCSIESPR
| Q4 25 | 8.4% | — | ||
| Q3 25 | 50.6% | — | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | 38.7% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 38.3% | -68.7% | ||
| Q2 24 | 18.1% | -9.9% | ||
| Q1 24 | 40.6% | 39.0% |
资本支出强度CCSIESPR
| Q4 25 | 9.1% | 0.0% | ||
| Q3 25 | 8.2% | 0.0% | ||
| Q2 25 | 9.1% | 0.0% | ||
| Q1 25 | 8.3% | 0.0% | ||
| Q4 24 | 9.2% | 0.0% | ||
| Q3 24 | 9.1% | 0.3% | ||
| Q2 24 | 9.8% | 0.1% | ||
| Q1 24 | 10.1% | 0.1% |
现金转化率CCSIESPR
| Q4 25 | 0.74× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.94× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.02× | — | ||
| Q1 24 | 1.69× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCSI
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
